Clinical trials: Gall Bladder Carcinoma
Gallbladder Cancer
AK112 Combined With GAP Conversion Therapy for Locally Advanced Gallbladder Cancer
The goal of this clinical trial is to evaluate the efficacy and safety of AK112 combined with the GAP regimen as conversion therapy for patients with locally advanced gallbladder cancer who are initially considered unsuitable for…
- Trial name
- ICORE-GBC (NCT07767994)
- Testing
- AK112, Gemcitabine, Cisplatin
- Volunteers
- 22 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Cholangiocarcinoma Cancer, Gallbladder Cancer
A Feasibility Phase II Study in the Treatment of Resected Cholangiocarcinoma, Gallbladder, Pancreatic and Ampullary Cancers
To assess the feasibility of administering induction chemotherapy with gemcitabine and docetaxel followed by concurrent radiation and continuous infusion 5FU and consolidation gemcitabine/docetaxel chemotherapy.
- Conditions
- Cholangiocarcinoma Cancer, Gallbladder Cancer, Pancreatic Cancer, Ampullary Cancer
- Trial name
- NCT00660699
- Testing
- Gemcitabine, Docetaxel, Radiation
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Washington University School of Medicine
Carcinoma, Intrahepatic Cholangiocarcinoma
Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer
This is a single-arm, exploratory study to evaluate the efficacy and safety of HAIC in combination with surufatinib and tislelizumab in the first line treatment of patients with unresectable or metastatic biliary tract cancer
- Conditions
- Carcinoma, Intrahepatic Cholangiocarcinoma, Gallbladder Cancer, Surufatinib
- Trial name
- NCT06134193
- Testing
- HAIC, Surufatinib, Tislelizumab
- Volunteers
- 41 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Biliary Tract Cancer, Cholangiocarcinoma
Feasibility Study of Multi-Platform Profiling of Resected Biliary Tract Cancer
This study is going to test the ability to successfully obtain results from certain personalized tests for patients with biliary tract cancers that are able to be surgically removed.
- Conditions
- Biliary Tract Cancer, Cholangiocarcinoma, Gallbladder Cancer, Intrahepatic Cholangiocarcinoma
- Trial name
- NCT04561453
- Testing
- Multi-Platform Profiling with Organoid Drug Sensitivity Screening and ctDNA Monitoring
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- University of Washington
Biliary Carcinoma, Gall Bladder Carcinoma
Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma
The purpose of this study is to see if an experimental drug, called copanlisib is effective and safe in treating adult participants with cholangiocarcinoma, when used in combination with gemcitabine and cisplatin.
- Conditions
- Biliary Carcinoma, Gall Bladder Carcinoma, Cholangiocarcinoma, Gastrointestinal Tumor
- Trial name
- NCT02631590
- Testing
- Cisplatin, Gemcitabine, Copanlisib
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Gallbladder Cancer Unresectable
Gemcitabine Hydrochloride, Cisplatin, Nab-Paclitaxel, and Durvalumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer
This phase II trail will evaluate the efficacy and safety of combining gemcitabine hydrochloride, cisplatin, nab-paclitaxel (paclitaxel albumin-stabilized nanoparticle formulation), with durvalumab in treating patients who have…
- Trial name
- GCND (NCT06591650)
- Testing
- gemcitabine hydrochloride, Cisplatin, Nab-paclitaxel
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Fudan University
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
S0202 Gemcitabine and Capecitabine for Unresectable Locally Advanced Metastatic Gallbladder Cancer or Cholangiocarcinoma
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and capecitabine, use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00033540
- Testing
- capecitabine, gemcitabine hydrochloride
- Where
- 112 sites in United States
- Volunteers
- 57 people
- Sponsor
- SWOG Cancer Research Network
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Liposomal Doxorubicin in Treating Patients With Liver or Bile Duct Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of liposomal doxorubicin in treating patients with liver…
- Conditions
- Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer
- Trial name
- NCT00003296
- Testing
- filgrastim, pegylated liposomal doxorubicin hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- Brown University
Biliary Tract Diseases, Gallbladder Cancer
Construction of Multicenter Retrospective Registry Cohort Database for Gallbladder Cancer
The aim of the study is to establishing a standardized clinical information database for patients with malignant tumors of gallbaldder.
- Conditions
- Biliary Tract Diseases, Gallbladder Cancer, Gallbladder Neoplasms
- Trial name
- CRGGCext (NCT06276153)
- Testing
- no interventions
- Volunteers
- 5,000 people
- Sponsor
- RenJi Hospital
Uterine Cervical Neoplasms, Triple Negative Breast Neoplasms
A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
This is a Phase 2 study of GV20-0251 in combination with anti-PD-1 monoclonal antibodies (including tislelizumab and toripalimab) for the treatment of participants with unresectable, locally advanced, or metastatic solid tumors…
- Conditions
- Uterine Cervical Neoplasms, Triple Negative Breast Neoplasms, Prostatic Neoplasms, Squamous Cell Carcinoma of Head and Neck
- Trial name
- NCT07623642
- Testing
- GV20-0251, anti-PD-1 monoclonal antibodies
- Where
- 2 sites in China
- Volunteers
- 227 people
- Sponsor
- GV20 Therapeutics
Cancer Pain, Visceral Pain
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
Patients with digestive tract malignancy often experience severe and unremitting abdominal pain that negatively affects physical, emotional, and social function, as well as health related quality of life (HRQOL).
- Conditions
- Cancer Pain, Visceral Pain, Gastrointestinal Neoplasms, Cancer of Gastrointestinal Tract
- Trial name
- NCT04907643
- Testing
- PICO G2 4k
- Where
- United States
- Volunteers
- 360 people
- Sponsor
- Cedars-Sinai Medical Center
Peripheral T Cell Lymphoma, Diffuse Large B Cell Lymphoma
A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies
This study evaluates the efficacy, as measured by the objective response rate, of STI-3031, an anti-PD-L1 antibody, in previously treated patients with selected advanced lymphomas or biliary tract cancer.
- Conditions
- Peripheral T Cell Lymphoma, Diffuse Large B Cell Lymphoma, Biliary Tract Cancer, Extranodal NK T Cell Lymphoma, Nasal
- Trial name
- NCT03999658
- Testing
- STI-3031
- Sponsor
- Sorrento Therapeutics, Inc.
Advanced or Metastatic Solid Tumor
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
This is a Phase 1a/1b, dose-escalation/expansion, consecutive-cohort, open-label study to evaluate the safety, tolerability, PK, PD, and preliminary evidence of antitumor activity of PLN-101095 in combination with pembrolizumab…
- Trial name
- NCT06270706
- Testing
- PLN-101095, Pembrolizumab
- Where
- 22 sites in United States, Spain
- Volunteers
- 124 people
- Sponsor
- Pliant Therapeutics, Inc.
Cholangiocarcinoma Non-resectable, Cholangiocarcinoma, Intrahepatic
Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma
The study is being conducted to assess the safety and tolerability of (1) PEGPH20 in combination with CIS and GEM (PEGCISGEM), and (2) PEGPH20 in combination with CIS, GEM, and atezolizumab (PEGCISGEMATEZO) compared with (3)…
- Conditions
- Cholangiocarcinoma Non-resectable, Cholangiocarcinoma, Intrahepatic, Cholangiocarcinoma, Extrahepatic, Gallbladder Adenocarcinoma
- Trial name
- NCT03267940
- Testing
- PEGPH20, CIS, GEM
- Where
- 36 sites in United States, South Korea and 1 more
- Volunteers
- 85 people
- Sponsor
- Halozyme Therapeutics
Biliary Tract Cancer
Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer
NuTide:121 compares NUC-1031 with gemcitabine, both in combination with cisplatin, in patients with previously untreated advanced biliary tract cancer.
- Trial name
- NCT04163900
- Testing
- NUC-1031, Gemcitabine, Cisplatin
- Where
- 125 sites in United States, Australia and 13 more
- Volunteers
- 773 people
- Sponsor
- NuCana plc
Pancreas Cancer, Pancreatic Cancer
Quebec Pancreas Cancer Study
The Quebec Pancreas Cancer Study is a prospective clinic-based study consisting of clinical, family history and epidemiologic data, with accompanying biospecimens, from patients diagnosed with either pancreas cancer, a related…
- Conditions
- Pancreas Cancer, Pancreatic Cancer, Pancreas Neoplasm, Pancreas Cyst
- Trial name
- QPCS (NCT04104230)
- Where
- Canada
- Volunteers
- 2,000 people
- Sponsor
- George Zogopoulos
Hepatocellular Carcinoma, Cholangiocarcinoma
Hepatobiliary Tumors Tissue Samples Acquisition
Hepatobiliary tumors have a poor prognosis and high individual heterogeneity, so it is of great significance to find important prognostic markers and then screen out specific subgroups of people; meanwhile, chronic hepatitis…
- Conditions
- Hepatocellular Carcinoma, Cholangiocarcinoma, Gallbladder Cancer, Biliary Tract Cancer
- Trial name
- NCT04445532
- Testing
- Gene expression analysis, Genomic analysis, Protein expression analysis
- Where
- China
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Peking Union Medical College Hospital
Cholangiocarcinoma, Stage III Gallbladder Cancer AJCC v7
TAS-102 in Treating Advanced Biliary Tract Cancers
This phase II trial studies how well trifluridine/tipiracil hydrochloride combination agent TAS-102 (TAS-102) works in treating participants with biliary tract cancers that have spread to other places in the body.
- Conditions
- Cholangiocarcinoma, Stage III Gallbladder Cancer AJCC v7, Stage IIIA Gallbladder Cancer AJCC v7, Stage IIIB Gallbladder Cancer AJCC v7
- Trial name
- NCT03278106
- Testing
- Laboratory Biomarker Analysis, Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- Mayo Clinic
Gallbladder Cancer
Envafolimab Combined With GEMOX in First-line Treatment of Advanced GBC
The TOPAZ-1 study compared the advantages and disadvantages of immune checkpoint inhibitor anti-PD-L1 antibody combined with Gem/Cis chemotherapy (Gemcitabine and Cisplatin) and Gem/Cis chemotherapy alone in first-line treatment…
- Trial name
- NCT06013943
- Testing
- Envafolimab+Gemox
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Extrahepatic Bile Duct Cancer, Pancreatic Cancer
Two-in-one Covered and Uncovered Metal Stent
Endoscopic placement of a self-expandable metal stent (SEMS) is the principle method for palliation of inoperable malignant distal biliary obstruction.
- Conditions
- Extrahepatic Bile Duct Cancer, Pancreatic Cancer, Lymph Node Metastases, Gallbladder Cancer
- Trial name
- NCT04337333
- Testing
- Two-in-one stent
- Where
- 2 sites in South Korea
- Volunteers
- 100 people
- Sponsor
- Ajou University School of Medicine